Description
Despite FDA warnings and a 315% increased erythrocytosis risk with TRT, the association between elevated hematocrit and actual VTE events remains inconclusive. This uncertainty hampers evidence-based risk-benefit decisions for millions of aging men considering TRT.
Gap type: open_question Source paper: Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. (2015, Sexual medicine reviews, PMID:27784544)
Resolution criteria
Resolution requires: (1) A prospective cohort study (n≥5000 TRT users, ≥3 years follow-up) with hematocrit monitoring, stratified by erythrocytosis severity (Hct 50-52.5%, 52.5-55%, >55%), demonstrating quantified absolute risk increase (or non-inferiority) for VTE events (DVT, PE) per hematocrit tertile with HR confidence intervals; (2) Mechanistic coagulation studies in TRT-treated men showing whether erythrocytosis correlates with ≥2 validated thrombosis markers (e.g., thrombin generation, TEG/ROTEM clot strength, platelet aggregation) with a threshold Hct level predicting hemostatic change; (3) Pharmacokinetic modeling or Mendelian randomization analysis demonstrating whether TRT-induced polycythemia is causally associated with thrombosis risk independent of testosterone levels and baseline cardiovascular risk factors.